Fujian Cosunter Pharmaceutical Co.Ltd(300436)
On the 13th meeting of the 4th board of directors by independent directors
Prior approval opinions on relevant matters
In accordance with the guiding opinions on the establishment of independent director system in listed companies, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies, the articles of association, the company’s independent director working system and relevant laws and regulations, As an independent director of Fujian Cosunter Pharmaceutical Co.Ltd(300436) (hereinafter referred to as “the company”), we reviewed the proposal of the 13th meeting of the 4th board of directors in advance, and issued the following prior approval opinions on the basis of knowing relevant information:
1、 Prior approval opinions on the renewal of the company’s accounting firm in 2022
After verification, Dahua Certified Public Accountants (special general partnership) has the business qualification related to securities and futures, has the experience and ability to provide financial report audit and various special audit services for listed companies, and can meet the requirements of the company’s financial report audit and various special audits; This appointment complies with relevant laws, regulations and the articles of association, and does not harm the interests of the company and minority shareholders. Therefore, it is agreed that the company will continue to employ Dahua Certified Public Accountants (special general partnership) as the company’s accounting firm in 2022, and it is agreed to submit it to the 13th meeting of the Fourth Board of directors for deliberation.
2、 Prior approval opinions on signing technology development (cooperation) contract and related party transactions
After verification, this connected transaction is conducive to give full play to the advantages of both parties and promote the innovation and R & D of the company. The transaction price refers to the fair price of the market. After negotiation and determination by both parties, there is no situation that damages the interests of the company and other shareholders, especially small and medium-sized shareholders. We unanimously agreed to submit the proposal on signing technology development (cooperation) contract and related party transactions to the 13th meeting of the Fourth Board of directors of the company for deliberation. When the board of directors deliberates the above related party transactions, the related directors Mr. Li Guoping, Mr. Li Guodong and Ms. Ye Liqing shall withdraw from voting. (no text below)
(there is no text on this page, which is the signature page of Fujian Cosunter Pharmaceutical Co.Ltd(300436) independent director’s prior approval opinions on matters related to the 13th meeting of the 4th board of directors) signature of independent director:
Ren Hong, Chen Mingyu, Qiang Xinrong
Fujian Cosunter Pharmaceutical Co.Ltd(300436) board of directors MM DD YY
